99 results about "Cyclic depsipeptide" patented technology

Many cosmetic stick compositions containing a continuous phase of a water-immiscible cosmetic oil structured by a fibre-forming amido structurant and an active cosmetic ingredient either exhibit poor physical stability when formed, or cannot be made readily using conventional processes for making stick compositions. The problem can be ameliorated or overcome by the use of a combination of amido structurants comprising in class (i) an N-acylaminoacid amide in which the N-acyl substituent has the formula —CO—RX in which RX represents a branched C6 to C11 alkyl group in combination with a further amido structurant, (class (ii), including a polyamido-substituted cyclohexane, an amido derivative of di or tricarboxylic acids or an hydroxystearamide and particularly employing an N-acylaminoacid amide in which the N-acyl substituent contains a linear alkyl group, or a cyclodipeptide.

The present application relates to cyclic depsipeptides of Formula I: or derivatives thereof, wherein X, A1, A2, A3, A4, A5, A6 and A7 are defined herein. The cyclic depsipeptides of Formula I are inhibitors of kallikrein 7 and thus can be employed for the treatment of kallikrein-7 dependent diseases.

The present invention provides 4-substituted-2-azetidinone compounds, bicyclic 2-5-diketopiperazine compounds, and pharmaceutical compositions thereof that are potent, safe and effective neuroprotective agents. Due to their strong central nervous system (CNS) activity, the compounds can be used to enhance memory and to treat a variety of neurological disorders. The compounds are particularly useful for treating neurological disorders caused by, or associated with, CNS trauma.

The invention belongs to the technical field of pharmaceutical synthesis, and discloses a pure solid-phase synthetic method of Halipeptin Orfamide A. The solid-phase synthetic method is used for efficient and mass production of the Halipeptin orfamide A.

The present application relates to cyclic depsipeptides, or derivatives thereof, having the structure of formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7 and human neutrophil elastase.

The invention provides an application of cyclo-dipeptide in preparation of a drug for treating gastrointestinal ulcer. The cyclo-dipeptide is cyclo-L-Pro-L-alanine dipeptide. The dipeptide is small in molecular weight and is simple in structure, has significant treatment effects on the gastrointestinal ulcer, can enter blood circulation quickly through mucous membrane tissue during treatment, can avoid first pass effect in liver and quickly arrive at lesion, achieves the best treatment effect on the gastrointestinal ulcer, is reduced in treatment time and use quantity and is also reduced in relapse rate.

The invention provides cyclic dipeptide used for wound healing. The cyclic dipeptide is one of ala-gly and ala-leu. The cyclic dipeptide has remarkable therapeutic effect on wound. Inhibition rate of acute and chronic gastric ulcer is high, wound healing speed of burns and scalds is fast, and scars are shallow.

The invention discloses a synthesis method of a cyclic dipeptide. A cyclic dipeptide sequence contains L-asparagine or L-glutamine. The method comprises the following steps: by taking 2-Chlorotrityl Chloride Resin as a carrier, carrying out solid-phase synthesis to obtain a straight-chain dipeptide fragment H-Glu-AA-OH or H-Asp-AAOH, wherein AA is other alpha-amino acids except asparagine, glutamine, glutamic acid, aspartic acid and cysteine; then carrying out a methyl esterification reaction to obtain straight-chain dimethyl ester protected dipeptide H-Glu (OMe) -AA-OMe or H-Asp (OMe)- AA-OMe; then carrying out water-phase alkaline cyclization to obtain cyclic dipeptide Cyclo[ Glu (OMe)- AA] or Cyclo[ Asp (OMe)- AA] protected by side chain carboxyl methyl ester; and finally, carrying outammonolysis to obtain the cyclic dipeptide containing glutamine or asparagine. The method is simple in synthesis process and safe to operate, incomplete cyclization caused by steric hindrance of aminoacid side chain protecting groups in the cyclization process is effectively avoided, few byproducts are produced, purification is easy, and cyclic dipeptide containing Gln and Asn can be synthesizedin batches.

The present application relate to cyclic depsipeptides, or derivatives thereof, having the formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7.

The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasites in or on mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.

The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals, including humans. The compounds and compositions may be used for combating parasites in or on animals including mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in animals, including birds and mammals.

The present invention relates to novel cycloundecadepsipeptide compounds and their analogues which bind and inhibit cyclophilins, have reduced immunosuppressive activity and improved physicochemical properties including water solubility. The present invention further relates to pharmaceutical compositions containing said depsipeptide compounds and their analogues for use in the treatment or prevention of diseases and pathologies which may be ameliorated by the inhibition of cyclophilin activity.

The invention discloses a cyclic dipeptide C2 with an avian influenza-resisting activity, which is separated from fermentation broth and fruiting bodies of phellinus igniarius (LexFr) Quel (phellinus linteus (BerketCurt) Teng, phellinus baumii and phellinus hartigii (AlleschetSchnabl) Imaz). The invention firstly discloses a new activity of the cyclic dipeptide and proves that the cyclic dipeptide has an avian influenza-resisting action. Compared with the application of a general compound, the method has the advantages that the special new activity of the cyclic dipeptide is found, and the cyclic dipeptide has the action of resisting the avian influenza virus.

The invention discloses a cyclic dipeptide C7 with anti-avian influenza activity separated from Phellinus igniarius (LexFr) Quel (phellinus linteus (BerketCurt) Teng, Phellinus baumii, Phellinus hartigii (AlleschetSchnabl) Imaz) fermentation liquid and sporophores. The invention discloses new activity of cyclic dipeptide. The cyclic dipeptide is proved to have an anti-avian influenza action. Compared with the application of common compounds, the method detects the new activity of the cyclic dipeptide, and the cyclic dipeptide has the anti-avian influenza action.